Requires covered entities report to the department of health regarding certain 340B drug discounts and what percentage of patients benefit from such discounts.

This bill requires certain health organizations to report to the New York Department of Health about discounts on medications they receive through the 340B program. It specifically focuses on how many patients benefit from these discounts, aiming to provide transparency about the program's impact on patient care.

Supporters of the bill argue that it promotes transparency and accountability in the healthcare system. By requiring reports on how many patients benefit from the 340B drug discounts, the bill ensures that these savings are reaching those who need them most, ultimately improving access to affordable medications.

Critics may argue that the bill adds unnecessary bureaucratic requirements for healthcare providers already facing financial pressures. They might contend that the focus on reporting could divert attention from more pressing issues in healthcare and complicate the administration of the 340B program.